Look at some landmark studies. Take the LEADER trial published last ADA. It showed a significant reduction in CV events in a compromised cardiac patient having diabetes independent of statins, ARBs and platelet inhibitors. It has established liraglutide in the diabetes world.
Similarly, empagliflozin in the EMPA-REG study is another landmark study popularizing the CVOT benefits in a diabetes patient. So much so that now USFDA has made it mandatory that any new antidiabetic that has to come out in clinical parlance can be approved as an antidiabetic only if it shows CVOT benefits. There are many such landmark innovator molecules that have changed the medical therapeutic armamenteria across the globe and have generated international guidelines that we respect as evidence based medicine or state of the art medicine. Over the years the entire faculty of allopathic medicine rests its…
